The cohort included HER2 low and ultralow expression cancers were considered HER2 negative, i.e. HER2 (1+) or HER2 (2+/FISH negative) with either hormone receptor-positive (ER 3+, PR 3+) or negative (ER -, PR -) status (Table 4). This evidence concerns the gene PGR and cancer.